Ratios of activated matrix metalloproteinase‐9 to tissue inhibitor of matrix metalloproteinase‐1 in wound fluids are inversely correlated with healing of pressure ulcers

Previous analyses of fluids collected from chronic, nonhealing wounds found elevated levels of inflammatory cytokines, elevated levels of proteinases, and low levels of growth factor activity compared with fluids collected from acute, healing wounds. This led to the general hypothesis that chronic inflammation in acute wounds produces elevated levels of proteinases that destroy essential growth factors, receptors, and extracellular matrix proteins, which ultimately prevent wounds from healing. To test this hypothesis further, pro‐ and activated matrix metalloproteinases (MMP‐2 and MMP‐9), tissue inhibitors of metalloproteinases (TIMP‐1 and TIMP‐2), and the ratios of MMPs/TIMPs were assayed in fluids and biopsies collected from 56 patients with chronic pressure ulcers. Specimens included ulcers treated for 0, 10, and 36 days with conventional therapy or with exogenous cytokine therapies. Quantitative assay data were correlated with the amount of healing. The average MMP‐9/TIMP‐1 ratio in fluids from 56 ulcers decreased significantly as the chronic pressure ulcers healed. Furthermore, the average MMP‐9/TIMP‐1 ratio was significantly lower for fluids collected on day 0 from wounds that ultimately healed well (≥85% reduction in initial wound volume) compared with wounds that healed poorly (<50% wound volume reduction). These data show that the ratio of MMP‐9/TIMP‐1 levels is a predictor of healing in pressure ulcers and they provide additional support for the hypothesis that high levels of MMP activity and low levels of MMP inhibitor impair wound healing in chronic pressure ulcers.

[1]  M. Stacey,et al.  Mitogenic activity and cytokine levels in non‐healing and healing chronic leg ulcers , 2001, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[2]  Jerry S. Vandeberg,et al.  Sequential cytokine therapy for pressure ulcers: clinical and mechanistic response. , 2000, Annals of surgery.

[3]  D. Yager,et al.  The proteolytic environment of chronic wounds , 1999, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[4]  W. Parks.  Matrix metalloproteinases in repair , 1999, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[5]  G. Schultz,et al.  Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors , 1999, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[6]  C. Owen,et al.  Leukocyte proteinases in wound healing: roles in physiologic and pathologic processes , 1999, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[7]  K. Brandt,et al.  Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme. , 1999, Arthritis and rheumatism.

[8]  T. Tuan,et al.  Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase‐B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing , 1999, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[9]  I. K. Cohen,et al.  MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers. , 1999, The Journal of surgical research.

[10]  I. K. Cohen,et al.  Interleukin-1alpha and collagenase activity are elevated in chronic wounds. , 1998, Plastic and reconstructive surgery.

[11]  D. Chyatte,et al.  Identification of a serum gelatinase associated with the occurrence of cerebral aneurysms as pro-matrix metalloproteinase-2. , 1998, Stroke.

[12]  I. K. Cohen,et al.  Physiology of the chronic wound. , 1998, Clinics in plastic surgery.

[13]  D. Leaper,et al.  Postsurgical wound progression monitored by temporal changes in the expression of matrix metalloproteinase‐9 , 1997, The British journal of dermatology.

[14]  K. Scharffetter-Kochanek,et al.  Protease inhibitors protect growth factor activity in chronic wounds , 1997, The British journal of dermatology.

[15]  L. Moldawer,et al.  A MATRIX METALLOPROTEINASE INHIBITOR PREVENTS PROCESSING OF TUMOR NECROSIS FACTOR α (TNFα) AND ABROGATES ENDOTOXIN‐INDUCED LETHALITY , 1997 .

[16]  R. Diegelmann,et al.  Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors , 1997, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[17]  I. K. Cohen,et al.  Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. , 1996, The Journal of investigative dermatology.

[18]  G. Schultz,et al.  Interactions of cytokines, growth factors, and proteases in acute and chronic wounds , 1996, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[19]  R. Tarnuzzer,et al.  Biochemical analysis of acute and chronic wound environments , 1996, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[20]  A. Vaheri,et al.  Matrix metalloproteinases, gelatinase and collagenase, in chronic leg ulcers. , 1996, The Journal of investigative dermatology.

[21]  M. Stacey,et al.  Biochemical analysis of wound fluid from nonhealing and healing chronic leg ulcers , 1996, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[22]  W. Cunliffe,et al.  Cytokine and protease levels in healing and non‐healing chronic venous leg ulcers , 1995, Experimental dermatology.

[23]  C. N. Rao,et al.  Alpha 1-antitrypsin is degraded and non-functional in chronic wounds but intact and functional in acute wounds: the inhibitor protects fibronectin from degradation by chronic wound fluid enzymes. , 1995, The Journal of investigative dermatology.

[24]  A. Rogers,et al.  Involvement of proteolytic enzymes—plasminogen activators and matrix metalloproteinases—in the pathophysiology of pressure ulcers , 1995, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[25]  M. Longaker,et al.  Tissue inhibitor of metalloproteinases-1 is decreased and activated gelatinases are increased in chronic wounds. , 1995, The Journal of investigative dermatology.

[26]  W. Stetler-Stevenson,et al.  Quantitative zymography: detection of picogram quantities of gelatinases. , 1994, Analytical biochemistry.

[27]  R. Poorman,et al.  Interstitial collagenase is required for angiogenesis in vitro. , 1994, Developmental biology.

[28]  A. Mauviel.  Cytokine regulation of metalloproteinase gene expression , 1993, Journal of cellular biochemistry.

[29]  W. Eaglstein,et al.  Inhibition of cell proliferation by chronic wound fluid , 1993, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[30]  F. Grinnell,et al.  Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. , 1993, The Journal of investigative dermatology.

[31]  G. Schultz,et al.  Growth factors and wound healing: Part II. Role in normal and chronic wound healing. , 1993, American journal of surgery.

[32]  G. Schultz,et al.  Growth factors and wound healing: biochemical properties of growth factors and their receptors. , 1993, American journal of surgery.

[33]  F. Grinnell,et al.  Fibronectin profiles in normal and chronic wound fluid. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[34]  M. Fini,et al.  The pattern of metalloproteinase expression by corneal fibroblasts is altered by passage in cell culture. , 1990, Journal of cell science.

[35]  Gary R. Grotendorst,et al.  Two peptides related to platelet-derived growth factor are present in human wound fluid. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Robson,et al.  Pressure Sore Volume Measurement: A Technique to Document and Record Wound Healing , 1988, Journal of the American Geriatrics Society.

[37]  J. Seyer,et al.  Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase. , 1985, The Journal of biological chemistry.

[38]  L. Moldawer,et al.  A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor alpha (TNF alpha) and abrogates endotoxin-induced lethality. , 1997, Shock.